The therapeutic use of monoclonal antibodies in colorectal carcinoma

Seminars in Oncology

Volumn 18, Issue 5, 1991, Pages 462-477

  Mellstedt, Håkan ^a   Frödin, Jan Erik ^a   Masucci, Giuseppe ^a   Ragnhammar, Peter ^a   Fagerberg, Jan ^a   Hjelm, Anna Lena ^a   Shetye, Jayant ^a   Wersäll, Peter ^a   Österborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGY; CANCER IMMUNOTHERAPY; COLORECTAL CARCINOMA; HUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW;

ANIMAL; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; CYTOKINES; HUMAN; IMMUNOTOXINS; SUPPORT, NON-U.S. GOV'T;

EID: 0025995425     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (90)

1. Efficient selection of human tumor growth-inhibiting monoclonal antibodies
2. A monoclonal antibody defined antigen associated with gastrointestinal cancer is a ganglioside containing sia-lylated lac tp-N-fuco-pentaose II
3. Isolation and characterization of a carcinoma-associated antigen
4. Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody: Isolation and characterization by mass spectrometry and NMR spectroscopy
5. Specific carcinoembryonic antigens of the human digestive system
6. Monoclonal antibodies against gastrointestinal tumor-associated antigens isolated as monosialogangliosides
7. 2A isotype containing increased numbers of macrophages activated for distinctive form of antibody dependent cytolysis
8. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A)
9. Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948)
10. 3 subclass
11. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies
12. 4 chimeric monoclonal antibodies with anti-tumor specificity
13. Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen
14. Treatment of B cell lymphomas with anti-idiotype antibodies alone and combination with α-IFN
15. Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotypes
16. Remission induction in non-Hodgkins lymphoma with reshaped human monoclonal antibodies to Campath-1H
17. Antiidiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy
18. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF)
19. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules
20. Death and the cell
21. Cell death: The significance of apoptosis
22. Monoclonal antibody mediated tumor regression by induction of apoptosis
23. Human antiidiotype antibodies in cancer patients Is the modulation of the immune response beneficial for the patient?
24. Towards a network theory of the immune system
25. Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients
26. The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma
27. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas
28. Treatment of patients with metastazing colorectal carcinoma with mouse monoclonal antibodies (Moab 17-1A); A progress report
29. Monoclonal antibodies (MAb 17-1A) for the treatment of patients with metastatic colorectal carcinomas
30. Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma
31. D3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites
32. Studies on B lymphoid tumors treated with monoclonal antiidiotype antibodies: Correlation with clinical responses
33. 1) relation to the clinical outcome: An important antitumoral effector function
34. Antiidiotype antibodies in cancer patients receiving monoclonal antibody to carcinoembryonic antigen
35. Anti-idiotypic antibodies to monoclonal antibody CO17-1A
36. Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies
37. Development of anti-idiotypic antibodies against tumor antigens and auto-antigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies
38. Antiidiotype immunization of cancer patients: Modulation of the immune response
39. Design and analysis of randomized clinical trials requiring prolonged observation of each patient II Analysis as examples
40. Time dependent covariants and further remarks on likelihood construction
41. Pitfalls in epidemiological research: An examination of the asbestos literature
42. Therapy of disseminated murine leukemia with cyclophosphamide and immune LYT1 + 2-T cells. Tumor erradication does not require participation of cytolytic T cells
43. Human monoclonal anti-idiotypic antibodies against a murine monoclonal antibody (MAb17-1A) as an anti-tumor vaccine
44. 2)
45. Cancer immunotherapy: Why are clinical results discouraging—Can they be improved?
46. Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity
47. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide
48. Isolation and characterization of autologous blood mononuclear cells used for auto-infusion together with monoclonal antibodies in tumor treatment
49. Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: A preliminary report
50. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma
51. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects
52. Phase I study of high-dose serotherapy with cytotoxic monoclonal antibodies in patients with gastrointestinal malignancies
53. Monoclonal antibodies specific immunotherapy of gastrointestinal tumors
54. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma
55. Treatment of gastrointestinal cancer using monoclonal antibodies
56. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian and lung cancer
57. Antibody therapy
58. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen
59. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody dependent cellular cytotoxicity
60. Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb17-1A: A combination of potential usefulness in tumor therapy
61. TNF-α and leukocyte α-IFN enhance IL-2 activated killer cell activity against tumor cells in the absence or presence of monoclonal antibodies
62. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2 induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (MAb 17-1A)
63. Interleukin-4 (IL-4) augments the cytotoxic capacity of lymphocytes and monocytes in antibody dependent cellular cytotoxicity
64. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma
65. Antibody delivery and effector cell activation in a phase II trial of recombinant γ-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma
66. Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor
67. Diphtheria toxindependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis
68. On the mechanism of protein-synthesis inhibition by abrin and ricin Inhibition of the GTP-hydrolysis site on the 60-S ribosomal subunit
69. Structural determinants or Ricinus communis agglutinin and toxin specificity for oligosaccarides
70. Diphtheria toxin receptor. Identification of specific diphtheria toxin-binding proteins on the surface of Vero and BS-C-1 cells
71. Immunotoxins containing ricin
72. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain monoclonal antibody 791 T/36 conjugates
73. Phase I study of monoclonal antibody-ricin-A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer
74. Phase I–II study of a ricin monoclonal antibody conjugate in colon cancer
75. Design and therapeutic evaluation of monoclonal antibody 791T/36-methotrexate conjugates
76. Antitumor properties of vindesine monoclonal antibody conjugates
77. Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer
78. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas
79. Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma
80. 131-labeled antibodies in ovarian, colonic and brain tumours
81. Repeated antitumour antibody therapy in man with suppression of the host response by Cyclosporin A
82. Large Bowel
83. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
84. Restoration by levamisole of low E-rosette forming cells in patients suffering from various diseases
85. Prognostic value of in vitro tests of lymphocyte reactivity in colorectal carcinoma
86. Expression of histocompatibility antigens and characterization of mononuclear cell infiltrates in normal and neoplastic colorectal tissues of humans
87. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette Guerin vaccine
88. Five-year follow-up of a controlled trial of active specific immunotherapy in colorectal cancer
89. Idiotype vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotopes